BK Technologies Corporation filed a Form 8-K with the SEC on November 12, 2026, reporting its financial and operating results for the third quarter ended September 30, 2026, alongside a scheduled earnings conference call and webcast.
Southport Acquisition Corp. II filed a Form 8-K on November 12, 2026, announcing that holders of its IPO units may elect to separately trade the Class A ordinary shares and warrants included in those units beginning November 16, 2026.
KBR, Inc. filed a Form 8-K on November 12, 2026, under Item 7.01 Regulation FD, announcing an investor day held that same date for Trinzic, Inc., currently a wholly owned subsidiary of KBR.
D-Wave Quantum Inc. filed a Form 8-K with the SEC on November 12, 2026, disclosing that the company has been recognized as a Market Shaper in the Gartner Emerging Market Quadrant for Quantum Computing - Established Vendors as of November 2026.
NIQ Global Intelligence plc filed a Form 8-K on November 12, 2026, disclosing both its financial results for the nine months ended September 30, 2026, and a newly approved share repurchase program of up to $150.0 million.
BK Technologies Corporation filed a Form 8-K on November 12, 2026, disclosing that its Board of Directors authorized a $5.0 million increase to its existing share repurchase program on November 11, 2026, bringing the total authorized amount to $10.0 million.
Alkermes Public Limited Company filed a Form 8-K on November 12, 2026, disclosing that two of its wholly-owned indirect subsidiaries entered into a confidential settlement and license agreement with Teva Pharmaceuticals, Inc. on November 6, 2026, resolving a patent infringement lawsuit over all dosage …
StepStone Group Inc. filed a Form 8-K on November 12, 2026, disclosing that Co-Chief Operating Officer Jose A. Fernandez stepped down from his executive officer role effective November 11, 2026, and that Co-COO Jason P. Ment's title and responsibilities were simultaneously restructured.
Pelthos Therapeutics Inc. filed a Post-Effective Amendment No. 1 to two previously filed Form S-8 registration statements on November 12, 2026, to register rollover shares under its newly approved 2026 Equity Incentive Plan.
Pelthos Therapeutics Inc. filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 12, 2026, to register 500,000 shares of common stock issuable under its newly adopted 2026 Equity Incentive Plan.